RayKnowChina Research Map
Shortlist

RecruitingLung cancerN/A

Registered title, quoted from ClinicalTrials.gov

Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04944563, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. ECOG score of 0,1 or 2;

    Inclusion criterion 5

  3. A history of other malignancies in the last 5 years (exclusion of early-staged thyroid cancer);

    Exclusion criterion 2

  4. Pregnant and lactating women;

    Exclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04944563, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patient aged 18-75 years old;
  • 6 mm ≤ tumor size ≤ 20 mm;
  • 0.25 < CTR < 1;
  • Center of tumor located in the middle third of the lung field;
  • ECOG score of 0,1 or 2;
  • Lung function (FEV1 ≥ 1 L and ≥ 70%);
  • Both lung segmentectomy and lobectomy could achieve R0 resection;
  • No serious cardiopulmonary complications, and could withstand both lung segmentectomy and lobectomy;
  • No hilus pulmonis and mediastinal lymph node metastasis and no distant metastasis;
  • Single tumor nodule or the concomitant nodule < microinvasive tumor;
  • Written informed consent.

Exclusion Criteria:

  • The tumor nodule is located in right middle lobe;
  • A history of other malignancies in the last 5 years (exclusion of early-staged thyroid cancer);
  • Have received preoperative anti-tumor therapy, including prior chemotherapy, radiation therapy, target therapy and so on;
  • A serious mental illness;
  • Pregnant and lactating women;
  • Congestive heart failure, myocardial infarction, severe stenosis of coronary artery within recent 6 months;
  • With the history of cerebral infarction or cerebral hemorrhage within 6 months;
  • With the history of sustained systemic corticosteroid therapy within 1 month;
  • The predicted surgical margin is less than 2 cm or the maximum diameter of the tumor at the 3D-CTBA
  • Other unsuitable situations;

Quoted from ClinicalTrials.gov, NCT04944563, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04944563, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04944563